key: cord-0686761-zs88279z
authors: Boyton, Rosemary J; Altmann, Daniel M
title: Risk of SARS-CoV-2 reinfection after natural infection
date: 2021-03-17
journal: Lancet
DOI: 10.1016/s0140-6736(21)00662-0
sha: 427166da0abe7915f16f60f5f045414655f41a87
doc_id: 686761
cord_uid: zs88279z

nan

Since the start of the COVID-19 pandemic, the question of potential reinfection has been ever present. Although there has been much debate about potential reliance on herd immunity through natural infection, human coronaviruses are well adapted to subvert immunity 1 and reinfection occurs for seasonal coronaviruses (229E, OC43, NL63, and HKU1) that cause the common cold due to ephemeral immunity that is poorly protective between infections. 2 Furthermore, detailed mapping of immune parameters in cohorts such as health-care workers emphasises the heterogeneity of immune responsiveness to SARS-CoV-2, from those with high neutralising antibody titres and broad T-cell repertoires, to the minority with barely detectable immunity. 3 These very low levels of immunity after infection would be hard to equate with protection from reinfection. Furthermore, among the longitudinal studies that have investigated waning antibody levels against SARS-CoV-2, responses have been found to last for 6 months or longer; although, depending on which components of the antibody repertoire are assayed, a substantial minority serorevert to negativity. 4, 5 Despite the substantial advances in all aspects of COVID-19 analysis and data collection over the past year, calculation of the risk of reinfection has been difficult and there are two key reasons for this. The most obvious reason for difficulty is that most individuals around the world who became infected during the first wave of the pandemic did not access a PCR or antibody test and were not admitted to or treated in hospital, and so are not included in many COVID-19 datasets. The second reason is that scientific journals require specific evidence for formal reporting of reinfection, leading to probable under-reporting. For instance, peer reviewers and editors have required evidence from individuals who tested positive by PCR, then recovered and became negative by PCR, and then subsequently tested positive by a second PCR test, with distinct sequenced viral isolates on each occasion. 6 Outside of a research cohort setting, such evidence gathering is rarely achievable and potential confounders exist to reinfection analysis. For example, a minority of individuals can harbour a reservoir of persistent SARS-CoV-2 in the gut, 7 such that distinguishing between true reinfection as opposed to recurrence of the original infection is challenging. A study of health-care workers in Sergipe, Brazil, indicated a relatively high rate of reinfections correlated with the lowest antibody responses, 8 but in most cases the researchers could not confirm de-novo reinfection. From that study, the investigators estimated risk of reinfection to be approximately 7%. 8 In The Lancet, Christian Hansen and colleagues report their population study of a Danish cohort investigating the risk of becoming positive for SARS-CoV-2 by PCR for the second time, presumed to indicate reinfection. 9 The study makes use of data from Denmark's national PCR-testing strategy whereby approximately 4 million people took 10·6 million PCR tests. Because the data in the system were person-identifiable, the authors were able to determine that 3·27% of those who were uninfected during the first surge had a positive test during the second surge, compared with 0·65% among those who had previously recorded a positive test. Thus, they determined from that, in general, past infection confers 80·5% protection against reinfection, which decreases to 47·1% in those aged 65 years and older. Hansen and colleagues acknowledge the many limitations of their analysis being restricted to only PCR data, including the possibility that people might change their behaviour after a positive PCR test. This confounder is addressed by noting that the findings are similar in a sensitivity analysis of nurses, doctors, social workers, and health-care assistants who were tested regularly due to their profession.

Set against the more formal reinfection case reports that are based on differential virus sequence data and make reinfection appear an extremely rare event, many will find the data reported by Hansen and colleagues about protection through natural infection relatively alarming. Only 80·5% protection from reinfection in general, decreasing to 47·1% in people aged 65 years and older are more concerning figures than offered by previous studies. Until now, one of the largest datasets has come from Qatar during a period of high disease burden and reported an estimated reinfection risk of 0·2%. 10 However, a key difference between the studies is that the Danish study is based on a universally accessible national testing programme for both symptomatic and non-symptomatic individuals, whereas the Qatar data are derived from a programme of PCR testing in the context of symptomatic disease. PCR-positive cases within the Danish dataset are thus likely to encompass a far higher proportion of asymptomatic cases presumed to elicit more marginal levels of protective immunity.

The quality, quantity, and durability of protective immunity elicited by natural infection with SARS-CoV-2 are poor relative to the much higher levels of virusneutralising antibodies and T cells induced by the vaccines currently being administered globally. 11, 12 Emergence of variants of SARS-CoV-2 with variable escape from natural and vaccine-induced immunity complicates matters further. Precise correlates of protection against SARS-CoV-2 are not known, but emerging variants of concern might shift immunity below a protective margin, prompting the need for updated vaccines. 13 Interestingly, vaccine responses even after single dose are substantially enhanced in individuals with a history of infection with SARS-CoV-2. 14 These data are all confirmation, if it were needed, that for SARS-CoV-2 the hope of protective immunity through natural infections might not be within our reach, and a global vaccination programme with high efficacy vaccines is the enduring solution.

Type I and type III interferons -induction, signaling, evasion, and application to combat COVID-19

Seasonal coronavirus protective immunity is short-lasting

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection

Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study)

Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting

Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Immunity to SARS-CoV-2 variants of concern

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals